GlobeNewswire

World Conference on Lung Cancer Wednesday Press Conference: Applying Conference Discoveries and Themes to the Real World

Share

TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- The final press briefing from the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) was led by conference co-presidents Natasha B. Leighl, M.D., BSc, MSc, and Gail Darling M.D., FRCSC, who reviewed the innovative work in lung cancer research and treatment presented over the course of the conference. “The future is bright, and I think we’ve seen that at this conference,” said Dr. Darling.

Paul A. Bunn Jr., M.D., distinguished professor, Division of Medical Oncology at the University of Colorado, provided an experienced practitioner’s view on the impact of this year’s practice-changing abstracts. Emphasizing that lung cancer is the leading cause of cancer deaths in the world and in men and women, Dr. Bunn said that the best thing to do is prevent it and to find it early. In commenting on the impact of “overwhelming” improvement in lung cancer mortality seen in the NELSON trial on randomized CT screenings, Dr. Bunn stated, “Even more than a coloscopy or a mammography, women in the world at risk for lung cancer should undergo an annual CT screening.”

Jill Feldman, lung cancer survivor and advocate, lost both parents, an aunt and a grandparent to lung cancer and shared her drive to advocate for an increase in research and treatment of this devastating disease. “When I look at these practice-changing abstracts, I know they’re exciting for clinicians, but for patients, they’re life changing,” Feldman said. “We must keep forging ahead, so others have the chance to watch their children grow up.”

Anna Farago, M.D., Ph.D., medical oncologist at Mass General Hospital, provided a young practitioner’s perspective on the practice-changing abstracts. In discussing the impact of the PACIFIC trial, Dr. Farago stated, “Based on the overall survival data we saw from the this trial presented at the WCLC, I think durvalumab is now solidified as the standard of care for Stage III unresectable non-small cell lung cancer following chemotherapy and radiation.”

In commenting on the IMpower133 trial, Dr. Farago concluded, “The standard of care/first line therapy for small cell lung cancer has been unchanged for 30 years. This is the first trial to demonstrate a clinically significant survival benefit.” 

Study analyzes use of thoracic radiotherapy for limited-stage SCLC
A recent study led by Xiao Hu, M.D., Ph.D., Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, demonstrated that using involved field radiotherapy (IFRT) and irradiating post-chemotherapy residual primary tumor volume for limited-stage small cell lung cancer (SCLC) did not result in increased recurrence of the cancer.

While combined chemotherapy and thoracic radiotherapy (TRT) is the standard of care for most patients with SCLC, TRT target volumes of limited-stage SCLC have been controversial. To date, this is the only prospective randomized study on these issues evaluating TRT for limited-stage SCLC.

“Considering the high malignancy and easy metastasis of SCLC, chemotherapy remains the cornerstone of comprehensive treatment,” said Dr. Hu. “For patients having difficulty with full-dose intravenous chemotherapy, it could be administered safely by dose reduction or using single agent chemotherapy or oral chemotherapy, along with radiotherapy.”

Read the full press release here.

Dr. Leighl closed the press briefing with a preview of today’s closing plenary, “The goal of this plenary is to help us take the great progress at this meeting—take it home, take action and really put this into practice.” 

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contacts:
Lisa Rivero
Vice President
lrivero@jpa.com | +1 617-657-1305
Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org | +1 720-254-9509

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 201916.7.2019 22:00:00 CESTPress release

LYON, France and CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: Appointment of Jean-Paul KRESS as director; he was subsequently appointed to the position of Chairman of the Board of Directors; Renewal of the term of office of each of the following as a member of the Board of Directors: o Gil BEYEN; o Luc DOCHEZ; o Philippe ARCHINARD; o Galenos, represented by Sven ANDREASSON; Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2018 and quietus of directors; Allocation of the financial year's results; Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; Approval of the regulations of the share subscription and/or purchase

LGC Capital Ltd. Announces Change in Financial Year-End16.7.2019 18:30:00 CESTPress release

MONTRÉAL, July 16, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) wishes to announce that it is changing its financial year-end to December 31 from its current year-end of September 30. As a result, LGC will file an additional interim report as at September 30, 2019 and will report audited financial results for a 15-month transition year from October 1, 2018 to December 31, 2019 (with a comparative of the 12 months ended September 30, 2018). Afterwards, LGC will revert to a customary reporting calendar based on a December 31 year-end, with fiscal quarters ending on the last day of March, June, September and December each year. LGC believes this change of financial year-end will allow it to complete the audit requirements of its investee companies with greater efficiency and will be useful to consolidate other companies in the future. The notice for the change in financial year-end required under Regulation 51-102 respecting Continuous Disclosure Obligations will b

UPDATE -- OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:53:00 CESTPress release

First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers Monetize Customer Relationships SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to addres

OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:00:00 CESTPress release

First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to address the complex customer identific

Agreement with Eurekahedge Expands eVestment’s Hedge Fund Data Offering16.7.2019 14:00:00 CESTPress release

ATLANTA, July 16, 2019 (GLOBE NEWSWIRE) -- eVestment, a global leader in institutional investment data and analytics, today announced an agreement with Eurekahedge to offer Eurekahedge fund data and indices to clients of eVestment’s suite of Analytics solutions. eVestment Analytics clients will now have access to Eurekahedge’s global hedge fund data and indices, which cover over 30,000 hedge funds and funds of hedge funds spanning North American, European, Asian, Latin American and emerging markets. This expansion of data capabilities on the eVestment platform furthers eVestment’s focus on providing the most comprehensive institutional investment data to clients around the world across a wide variety of asset classes, including traditional investment strategies, hedge funds, funds of hedge funds and private markets investment opportunities. “Our clients need the most comprehensive data available to make the best decisions,” said eVestment Global Head of Insights John Molesphini. “Addin

ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CESTPress release

Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be